BiotechTube

Reference: Follitropin alfa + Zoladex

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypogonadism

Conditions

Hypogonadism

Trial Timeline

Jul 21, 2025 → Dec 23, 2025

NCT ID
NCT07097259

About Reference: Follitropin alfa + Zoladex

Reference: Follitropin alfa + Zoladex is a phase 1 stage product being developed by Merck for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT07097259. Target conditions include Hypogonadism.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07097259Phase 1Completed

Competing Products

20 competing products in Hypogonadism

See all competitors
ProductCompanyStageHype Score
Topical Testosterone SolutionEli LillyApproved
85
Testosterone Solution + Placebo SolutionEli LillyPhase 3
77
Testosterone MD-LotionEli LillyPhase 2
52
Testosterone MD-LotionEli LillyPhase 3
77
Testosterone MD-LotionEli LillyPhase 3
77
Testosterone Gel 1.62% + Testosterone Gel 1.62%AbbViePhase 1
33
ABT-SLV176AbbViePhase 3
77
AndroGel® + PlaceboAbbVieApproved
85
AndroGel 1.62%AbbVieApproved
85
Recombinant human luteinizing hormone (r-hLH) + Recombinant human follicle-stimulating hormone (r-hFSH) + Human chorionic gonadotropin (hCG)MerckPhase 3
77
Oral testosterone undecanoate (Andriol) + PlaceboMerckPhase 2
52
Testosterone + Alendronate + Placebo Alendronate + Placebo TestosteroneMerckPhase 2
52
Testosterone Enanthate + FinasterideMerckPhase 2
52
Testim 1% (testosterone gel) + PlaceboMerckPhase 2
52
Investigational new drug company code: BGS649 + PlaceboNovartisPhase 2
52
Test formulation + Reference formulationPfizerPhase 1
32
Testosterone ProductBayerPre-clinical
20
Testosterone undecanoate (TU) - NebidoTMBayerPhase 3
74
Testosterone Undeconate (Nebido-R, BAY86-5037)BayerPre-clinical
20
Testosterone Undeconate (Nebido, BAY86-5037) + PlaceboBayerApproved
82

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85